Aandelen in “Biotechnologie”

Aandeel Datum Koers Evolutie
vlag Ultragenyx Pharmaceutical Inc. 18:06 42,290 USD
-0,75% 		-0,75%
vlag uniQure N.V. 18:06 5,035 USD
-0,69% 		-0,69%
vlag Unity Biotechnology Inc 18:02 1,505 USD
+2,38% 		+2,38%
vlag UroGen Pharma Ltd 18:06 13,260 USD
+0,38% 		+0,38%

Nieuws over “Biotechnologie”

05:45 · Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules · Persbericht

05:45 · Seelos Therapeutics Announces Pricing of $1.1 Million Registered Direct Offering and Concurrent Private Placement Priced At-the-Market Under Nasdaq Rules · Persbericht

00:46 · FDA APPROVES IMDELLTRA™ (TARLATAMAB-DLLE), THE FIRST AND ONLY T-CELL ENGAGER THERAPY FOR THE TREATMENT OF EXTENSIVE-STAGE SMALL CELL LUNG CANCER · Persbericht

16/05 · BLUE Investors Have Opportunity to Lead bluebird bio, Inc. Securities Fraud Lawsuit · Persbericht

16/05 · Monthly information on share capital and company voting rights · Persbericht

16/05 · DBV Technologies Announces Results of its 2024 Combined General Meeting · Persbericht

16/05 · Voting Rights and Shares Capital of the Company · Persbericht

16/05 · Galapagos creates new subscription right plans · Persbericht

16/05 · Galapagos creëert nieuwe inschrijvingsrechtenplannen · Persbericht

16/05 · Inventiva announces the positive recommendation of the fourth DMC of the NATiV3 Phase III clinical trial with lanifibranor in patients with MASH/NASH · Persbericht

16/05 · Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC · Persbericht

16/05 · Biogen and Ionis Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis · Persbericht

16/05 · Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis · Persbericht

16/05 · Ionis and Biogen Announce Topline Phase 1/2 Study Results of Investigational Drug in Amyotrophic Lateral Sclerosis · Persbericht

16/05 · Positive Clinical Results from HyBryte™ Compatibility Study in the Treatment of Cutaneous T-Cell Lymphoma Published in JEADV Clinical Practice · Persbericht

16/05 · Carisma Therapeutics Announces First Patient Dosed in Phase 1 Clinical Trial of CT-0525, a Novel HER2-Targeting CAR-Monocyte · Persbericht

16/05 · Compugen Publishes Paper in Cancer Immunology Research on Unique Biology of PVRIG and its Therapeutic Potential · Persbericht

16/05 · Ionis announces positive topline results from Phase 1/2a trial of ION582 for Angelman syndrome · Persbericht

16/05 · COLLPLANT BIOTECHNOLOGIES ANNOUNCES DATE FOR 2024 FIRST QUARTER FINANCIAL RESULTS AND CONFERENCE CALL INFORMATION · Persbericht

16/05 · Oncolytics Biotech® Announces Voting Results from the Annual General Meeting of Shareholders · Persbericht

16/05 · AMGEN TO HOST CONFERENCE CALL FOLLOWING ATS 2024 · Persbericht

Mijn selecties